CAPTRUST Financial Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-180
Closed -$9K 2283
2022
Q2
$9K Hold
180
﹤0.01% 3789
2022
Q1
$11K Hold
180
﹤0.01% 3733
2021
Q4
$15K Hold
180
﹤0.01% 3468
2021
Q3
$17K Hold
180
﹤0.01% 3264
2021
Q2
$18K Hold
180
﹤0.01% 3164
2021
Q1
$15K Hold
180
﹤0.01% 3181
2020
Q4
$16K Hold
180
﹤0.01% 2346
2020
Q3
$13K Hold
180
﹤0.01% 2170
2020
Q2
$13K Buy
+180
New +$11.5K ﹤0.01% 2089
2019
Q4
Sell
-180
Closed -$8K 1088
2019
Q3
$8K Hold
180
﹤0.01% 1556
2019
Q2
$9K Hold
180
﹤0.01% 1520
2019
Q1
$10K Hold
180
﹤0.01% 1378
2018
Q4
$8K Hold
180
﹤0.01% 1255
2018
Q3
$13K Hold
180
﹤0.01% 1148
2018
Q2
$10K Hold
180
﹤0.01% 1163
2018
Q1
$9K Hold
180
﹤0.01% 1045
2017
Q4
$10K Hold
180
﹤0.01% 977
2017
Q3
$10K Buy
180
+80
+80% +$4.55K ﹤0.01% 433
2017
Q2
$5K Buy
+100
New +$4.88K ﹤0.01% 240

Other funds holding BIB

CAPTRUST Financial Advisors's BIB Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2022, closing a stake of 180 shares — an estimated $9K sold.

CAPTRUST Financial Advisors first reported a position in BIB in Q2 2017 and held it in 19 quarters. The position peaked at $18K in Q2 2021. 19 funds tracked by Wall St. Rank hold BIB as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 180 ProShares Ultra NASDAQ Biotechnology shares in Q3 2022, an estimated $9K.
  • CAPTRUST Financial Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2017 and held it in 19 quarters.
  • CAPTRUST Financial Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $18K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.